These are operational milestones that reduce clinical trial timeline risk but do not change the company's financial outlook. Monitor for first patient dosing announcement and CTA approval in Germany as the next catalysts. No revenue or earnings data was provided in this filing.
Price Chart
Executive Summary
Silexion Therapeutics announced the initiation of GMP clinical batch manufacturing of its next-generation siRNA therapy SIL204 with Catalent, and received Helsinki Ethics Committee approval from Tel Aviv Sourasky Medical Center for its planned Phase 2/3 trial in locally advanced pancreatic cancer. These are operational milestones that advance the company toward first patient dosing but do not include any financial data or changes to the company's financial position.
Key Facts
- Initiated GMP clinical batch manufacturing of SIL204 with Catalent at its Limoges, France facility
- Received Helsinki Ethics Committee approval from Tel Aviv Sourasky Medical Center for Phase 2/3 trial of SIL204
- Drug substance for SIL204 was successfully manufactured in 2025 by a specialist global oligonucleotide CDMO
- Israeli Ministry of Health previously approved the Phase 2/3 trial; CTA submitted to Germany
- Phase 2/3 trial will evaluate SIL204 in combination with standard-of-care chemotherapy using dual-route administration
Financial Impact
No financial figures disclosed in the filing
Risk Factors
- Clinical trial enrollment and execution risks remain
- Company may need additional capital to complete the Phase 2/3 trial
- No guarantee of regulatory approval or clinical success for SIL204
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001178913-26-002624 |
| Exhibit: exhibit_99-1.htm | 0001178913-26-002624 |
| Document: 0001178913-26-002624-index-headers.html | 0001178913-26-002624 |
| Document: 0001178913-26-002624-index.html | 0001178913-26-002624 |
| Document: 0001178913-26-002624.txt | 0001178913-26-002624 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 29, 2026 21w ago | 8-K | $0.0334 | awaiting T+60 | — | — |
May 26, 2026 22w ago | 8-K | $0.0334 $0.0184 | ▼ −44.91% | ▼ −47.63% | — |
May 18, 2026 23w ago | 8-K | $0.0334 $0.0130 | ▼ −61.08% | ▼ −65.93% | — |
May 15, 2026 23w ago | 8-K | $0.0334 $0.0130 | ▲ +61.08% | ▲ +65.93% | — |
May 13, 2026 23w ago | 8-K | $0.0334 | awaiting T+60 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers